Dr. Brufsky on Adjuvant Bisphosphonates for Patients with Breast Cancer

Video

In Partnership With:

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.

Brufsky says he believes bisphosphonates are ready to be used in the adjuvant setting. Just as there was a meta-analysis for chemotherapy, there is a meta-analysis for adjuvant bisphosphonates. This analysis showed that 22,000 post-menopausal women experienced a survival benefit and disease-free survival benefit of about 3-4% when taking bisphosphonates. The data from this meta-analysis shows that adjuvant bisphosphonates are as significant as chemotherapy, Brufsky says.

Because of this, Brufsky believes that physicians are ready to use adjuvant bisphosphonates as a standard of care in breast cancer.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute